These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32925411)

  • 1. A Retrospective Review of Mercaptopurine Metabolism Reveals High Rate of Patients With Suboptimal Metabolites Successfully Corrected With Allopurinol.
    Vasta LM; Zanetti RC; Parekh DS; Warwick AB; Lieuw K
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1003-e1009. PubMed ID: 32925411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic Leukemia Avoids Mercaptopurine-related Hepatotoxicity.
    Giamanco NM; Cunningham BS; Klein LS; Parekh DS; Warwick AB; Lieuw K
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):147-51. PubMed ID: 26808368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of allopurinol to manage skewed 6-mercaptopurine metabolism in pediatric maintenance acute lymphoblastic leukemia treatment.
    Lines M; Kemper RM; Wallace J; Alexander T; Echols C; Garner LM; Kaplan JB; Thompson P; Crona DJ; Phillips K
    Eur J Haematol; 2024 Nov; 113(5):584-592. PubMed ID: 38989562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of allopurinol on 6-mercaptopurine metabolism in unselected patients with pediatric acute lymphoblastic leukemia: a prospective phase II study.
    Källström J; Niinimäki R; Fredlund J; Vogt H; Korhonen L; Castor A; Palle J; Harila A; Borssén M; Abrahamsson J; Ek T
    Haematologica; 2024 Sep; 109(9):2846-2853. PubMed ID: 38356449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity.
    Cohen G; Cooper S; Sison EA; Annesley C; Bhuiyan M; Brown P
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28360. PubMed ID: 32909665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allopurinol to Prevent Mercaptopurine Adverse Effects in Children and Young Adults With Acute Lymphoblastic Leukemia.
    Kamojjala R; Bostrom B
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):95-100. PubMed ID: 33750748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
    Brackett J; Schafer ES; Leung DH; Bernhardt MB
    Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
    Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment on the use of allopurinol to improve safety and efficacy of mercaptopurine in pediatric patients with Acute Lymphoblastic Leukemia and Lymphoma during maintenance therapy.
    Barone T; Dandekar S; McKeone D; Mulieri K
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1987. PubMed ID: 38351548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
    Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
    Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites.
    Miller MB; Brackett J; Schafer ES; Rau RE
    Pediatr Blood Cancer; 2019 Apr; 66(4):e27577. PubMed ID: 30548777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
    Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
    Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
    Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
    Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acral Skin Rash Caused by Altered Mercaptopurine Metabolism in Maintenance Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Newcome J; Geib KB; Thompson P; Gold S; Alexander TB
    J Pediatr Hematol Oncol; 2022 Oct; 44(7):398-401. PubMed ID: 35180762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.
    Adam de Beaumais T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2011 Apr; 71(4):575-84. PubMed ID: 21395650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
    Welch J; Lennard L; Morton GC; Lilleyman JS
    Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of Thiopurine Metabolites and Allopurinol in Pediatric Acute Lymphoblastic Leukemia: Consideration for an Algorithmic Approach.
    Mosher N; Torkildson J; Golden C; Raphael R; Beach B; Michlitsch J; Feusner JH; Agrawal AK
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e521-e525. PubMed ID: 34486570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
    Adam de Beaumais T; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL).
    Stuckert AJ; Schafer ES; Bernhardt MB; Baxter P; Brackett J
    Leuk Lymphoma; 2020 May; 61(5):1246-1249. PubMed ID: 31842647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.